Qingdao Haier Biomedical Co., Ltd. (688139.SH): The transfer price of this inquiry is 30.09 yuan/share.
Qingdao Haier Biomedical Co., Ltd. (688139. SH) announced on August 7th that based on the inquiry and application for subscription on August 7th, 2024, the preliminary transfer price for this inquiry is determined to be RMB 30.09 per share.
Qingdao Haier Biomedical Co., Ltd. (688139.SH): Shareholders plan to transfer 2% of their shares through inquiry-based pricing.
On August 6, Gelonhui reported that the shareholder who intends to participate in the pre-IPO shareholding inquiry transfer of Haier Biomedical (688139.SH) is Qijun Equity Investment Partnership Enterprise (Limited Partnership) of Meishan Bonded Port Area, Ningbo. The total number of shares to be transferred by the transferring party is 6,359,050 shares, accounting for 2.00% of the total share capital of the company. This inquiry transfer will not be conducted through centralized bidding or bulk trading, and is not a shareholding reduction through the secondary market. The transferee of the shares acquired through the inquiry transfer shall not transfer them within 6 months after acquisition.
Qingdao Haier Biomedical Co., Ltd. (688139.SH): The company has repurchased 0.26% of its shares.
Qingdao Haier Biomedical Co., Ltd. (688139.SH) announced on August 1st that as of July 31, 2024, the company has repurchased 815,617 shares through the Shanghai Stock Exchange trading system by means of centralized bidding trading, accounting for 0.26% of the total share capital of the company, with the highest repurchase price of RMB 32.31/share, the lowest price of RMB 27.40/share, and a total amount of RMB 25,654,978.48 (excluding transaction fees).
Is There Now An Opportunity In Qingdao Haier Biomedical Co.,Ltd (SHSE:688139)?
Qingdao Haier Biomedical's Unit Ups Stake in Subsidiary
Qingdao Haier Biomedical Co., Ltd. (688139.SH) plans to spend 21.8076 million yuan to acquire 2.53% equity of its subsidiary Haier Blood Technology (Chongqing).
Qingdao Haier Biomedical Co., Ltd., a wholly-owned subsidiary of Haier Biomedical (688139.SH), announced that...
Private Companies Are Qingdao Haier Biomedical Co.,Ltd's (SHSE:688139) Biggest Owners and Were Hit After Market Cap Dropped CN¥581m
Qingdao Haier Biomedical Co., Ltd. (688139.SH): Qijun Investment has completed the shareholding of 1.6% of the company's shares.
Qingdao Haier Biomedical Co., Ltd. (688139.SH) announced that as of the date of the announcement, its shareholder Ningbo Meishan Bonded Port Area Qijun Equity Investment Partnership (Limited Partnership) has...
Qingdao Haier Biomedical Co., Ltd. (688139.SH): did not repurchase shares in June.
On June 2024, Qingdao Haier Biomedical Co., Ltd. (688139.SH) announced that the company did not repurchase shares through the Shanghai Stock Exchange trading system through centralized bidding trading method. As of June 30, 2024, the company has repurchased 815,617 shares of the company through the Shanghai Stock Exchange trading system through centralized bidding trading method, accounting for 0.26% of the total share capital of 317,952,508 shares, with the highest repurchase price of 32.31 yuan/share and the lowest price of 27.40 yuan/share. The total amount of funds paid was RMB 25,654,978.4.
Investors Interested In Qingdao Haier Biomedical Co.,Ltd's (SHSE:688139) Earnings
Shareholder Qi Jun Investment of Qingdao Haier Biomedical Co., Ltd. (688139.SH) has cumulatively reduced its shareholding in the company by 1.29%.
Qingdao Haier Biomedical Co., Ltd. (688139.SH) announced that on June 11, 2024, the company received a shareholder's notice from Ningbo...
Qingdao Haier Biomedical Co., Ltd. (688139.SH) did not repurchase its shares in May.
On May 2024, Qingdao Haier Biomedical Co., Ltd. (688139.SH) announced that the company did not repurchase shares through the Shanghai Stock Exchange trading system by centralized bidding trading. As of May 31, 2024, the company has accumulated repurchased 815,617 shares through the Shanghai Stock Exchange trading system, accounting for 0.26% of the company's total equity of 317,952,508 shares, with a highest repurchased price of 32.31 yuan/share and a lowest repurchased price of 27.40 yuan/share. The total amount paid was RMB 25,654,978.4.
Haier Biotech (688139.SH) will distribute the 2023 cash dividend of 0.515 yuan per share on June 6
Haier Biotech (688139.SH) announced that the company will release the 2023 annual report on June 6, 2024...
Is Qingdao Haier BiomedicalLtd (SHSE:688139) A Risky Investment?
Haier Biotech (688139.SH): Major shareholder Qijun Investment plans to reduce the company's shares by no more than 1.6%
Haier Biotech (688139.SH) announced that the company holds 7.79% of the shares of Qijun in Ningbo Meishan Bonded Port Area...
Haier Biotech (688139.SH): Repurchase a total of 815,600 company shares
Gelonghui, May 6, 丨 Haier Biotech (688139.SH) announced that as of April 30, 2024, the company had repurchased a total of 815,617 shares through the Shanghai Stock Exchange trading system, accounting for 0.26% of the company's total share capital of 317,952,508 shares. The highest price of the repurchase transaction was RMB 32.31 per share, the lowest price was RMB 27.40 per share, and the total amount of capital paid was RMB 25,654,978.48 (excluding transaction fees).
Qingdao Haier Biomedical Co.,Ltd's (SHSE:688139) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Haier Biotech (688139.SH): Net profit of 138 million yuan in the first quarter increased 0.06% year over year
On April 25, GLONGHUI (688139.SH) released its first quarter report. Operating revenue was 687 million yuan, up 0.04% year on year, net profit of 138 million yuan, up 0.06% year on year, after deducting non-net profit of 130 million yuan, up 6.64% year on year, with basic earnings of 0.44 yuan per share.
Haier Biotech (688139.SH): 2.92 million restricted shares awarded to 262 incentive recipients
Gelonghui, April 18, 丨 Haier Biotech (688139.SH) announced that on April 18, 2024, the company held the 19th meeting of the 2nd board of directors, the 17th meeting of the 2nd board of directors, and the 2nd special meeting of independent directors to review and pass the “Proposal on Granting Restricted Shares for the First Time to Incentive Recipients”. It was determined that April 18, 2024 was the first grant date, and 2,920 million shares were awarded to 262 incentive recipients at an award price of 15.41 yuan/share.
Haier Biotech (688139.SH): A total cost of 25.488 million yuan to buy back 0.25% of the shares
Gelonghui, April 1, 丨 Haier Biotech (688139.SH) announced that as of March 31, 2024, the company had repurchased 809,606 shares of the company through centralized bidding transactions, accounting for 0.25% of the company's total share capital of 317,952,508 shares. The highest price of the repurchase transaction was 32.31 yuan/share, the lowest price was 29.55 yuan/share, and the total amount of capital paid was RMB 25,488,165.35 (not including transaction fees).
No Data